This site is intended for health professionals only
Tuesday 19 March 2019
Share |

Industry News

Six in 10 pharmacy professionals in favour of banning homeopathy prescribing

Friday 7th September 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.
 
In a congress session taking place at the International Pharmaceutical Federation’s (FIP) World Congress of Pharmacy and Pharmaceutical Science on Tuesday (4 September), 63% of between 150 to 200 people surveyed said ‘...

Mon, 27 Apr 2015
Following discussion with the Scottish Medicines Consortium (SMC) Janssen has requested that the SMC decision not to recommend the use of Zytiga® (abiraterone acetate) before chemotherapy for men with advanced prostate cancer in Scotland is referred to an Independent Review Panel.
Mon, 27 Apr 2015
ARIAD today welcomed the Scottish Medicine Consortium’s (SMC) acceptance to use Iclusig® (ponatinib) as a clinical and cost effective treatment for all phases of chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), in accordance with Iclusig’s licenced indication.
Mon, 27 Apr 2015
The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana®. The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or venous thromboembolism, involving 21,105 and 8,292 patients, respectively. Daiichi Sankyo looks forward to receiving approval decision by the European Commission soon, which is the basis for marketing authorisation in all European Union member states.
Mon, 27 Apr 2015
The European Commission has licenced Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).
Tue, 31 Mar 2015
Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.
Mon, 30 Mar 2015
Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.
Thu, 26 Mar 2015
The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine